[Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 Currently the Company is working diligently with the auditor to finish the audit and complete the 2014 10-K, and expect to file the 2014 Form 10-K within two weeks. Under NYSE MKT rules, until the Company files its Form 10-K, its common stock will] []
[Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 Currently the Company is working diligently with the auditor to finish the audit and complete the 2014 10-K, and expect to file the 2014 Form 10-K within two weeks. Under NYSE MKT rules, until the Company files its Form 10-K, its common stock will] []
[CURRENT REPORT FOR ISSUERS SUBJECT TO THE Amendment No. 3 to FORM 8-K CURRENT REPORT July 3, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041]
[CURRENT REPORT FOR ISSUERS SUBJECT TO THE Amendment No. 3 to FORM 8-K CURRENT REPORT July 3, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041]
[CURRENT REPORT FOR ISSUERS SUBJECT TO THE Amendment No. 2 to FORM 8-K CURRENT REPORT June 6, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041]
[FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE CURRENT REPORT May 28, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8551-6696 o o o]
[FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE CURRENT REPORT May 28, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8551-6696 o o o]
[TPI Reports Third Quarter Fiscal Year 2014 Financial Results Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the third quarter fiscal year 2014. Third Quarter Fiscal 2014 Ended March 31, 2014 Financial Highlights: · Revenue was $8.6] [Tianyin Pharmaceutical Inc. Third Quarter Fiscal Year 2014 Financial Results Conference Call May 15, 2014 Operator I will now turn the conference over to Dr. James Tong, Chief Financial Officer. Please go ahead. James Jiayuan Tong - Chief Financial Officer: Third quarter of fiscal year 2014 ended March 31, 2014 financial highlights. · Revenue was $8.6 million versus $15.5 million] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT May 15, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28- 8551-6696 o o]
[TPI Reports Third Quarter Fiscal Year 2014 Financial Results Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the third quarter fiscal year 2014. Third Quarter Fiscal 2014 Ended March 31, 2014 Financial Highlights: · Revenue was $8.6] [Tianyin Pharmaceutical Inc. Third Quarter Fiscal Year 2014 Financial Results Conference Call May 15, 2014 Operator I will now turn the conference over to Dr. James Tong, Chief Financial Officer. Please go ahead. James Jiayuan Tong - Chief Financial Officer: Third quarter of fiscal year 2014 ended March 31, 2014 financial highlights. · Revenue was $8.6 million versus $15.5 million] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT May 15, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28- 8551-6696 o o]
[FORM 10-Q (Mark One) x For the quarterly period ended March 31, 2014 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +86 028 8551 6696 (Address, including] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q0314ex32i_tianyin.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director EX-32.2 5 f10q0314ex32ii_tianyin.htm CERTIFICATION]
